Who this is for
Four groups, and the bodies treat them differently.
No symptoms, no family history. Neither body recommends a test. USPSTF's I statement applies to "adults, adolescents, and children who do not have signs or symptoms of celiac disease." ACG recommends against mass screening in the community, a strong recommendation on low-quality evidence with no dissent.
A parent, sibling or child with confirmed celiac disease. Here the bodies part. USPSTF found the evidence on targeted screening of people at increased risk, including those with a family history, inadequate, so its I statement covers relatives too. ACG's key concept for first-degree relatives who have no symptoms says "Consider testing" them. The rationale text in the same section says that patients with a first-degree family member with confirmed celiac disease "should be tested for CD," and later asks clinicians who find a family history to "consider screening the patient." Those are ACG's own words in one section, and none of them is a graded recommendation; ACG says key concepts are added to help implement its recommendations. Neither body gives a retesting interval. Where more than one family member already has celiac disease, ACG says screening then reaches every other family member, second-degree relatives included.
How likely is it? USPSTF puts the prevalence among people with a family history, counting first- or second-degree relatives, at an estimated 5% to 20%. ACG cites a rate as low as 5% among both first- and second-degree relatives in one large US multicenter study, and up to 20% in siblings and 10% in other first-degree relatives in other studies, especially community-based ones. These are two bodies' figures for differently defined groups, and we do not merge them.
Other conditions linked to celiac disease. USPSTF lists people with other autoimmune diseases as at increased risk, naming type 1 diabetes, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner syndrome, IgA deficiency and IgA nephropathy, and notes that several specialty societies recommend screening in these groups. ACG says people with type 1 diabetes should be tested if there are any suggestive symptoms or signs, and people with unexplained elevated liver enzymes should be assessed for celiac disease.
Symptoms change the question. Neither body's position on screening people without symptoms applies once you have symptoms. ACG says to test anyone whose symptoms, signs or lab results suggest malabsorption: chronic diarrhea with weight loss, fatty stools (steatorrhea), abdominal pain, bloating. USPSTF lists the classic symptoms as diarrhea, abdominal pain and weight loss, and less specific ones as anemia, osteoporosis, chronic fatigue, peripheral neuropathy or ataxia, and short stature, with mouth ulcers (aphthous stomatitis), dermatitis herpetiformis, infertility and recurrent fetal loss also on its list. It notes that some US patients may have symptoms for years before diagnosis.
Where the recommendations diverge
- USPSTF Evidence insufficient
- ACG Recommends against
- ACG Not age-bounded
- ACG Not age-bounded
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons.
Our note: The one I statement also covers people at higher risk: "The USPSTF also found inadequate evidence on the effectiveness of targeted screening in persons who are at increased risk for celiac disease (eg, persons with family history or other risk factors)." Literature scans in May 2024 "showed a lack of new evidence to support an updated systematic review on the topic at this time" (surveillance report dated August 21, 2024). No ages are stated, so both age fields are empty.
We recommend against mass screening for CD in the community
Our note: An excerpt of item 7B, which ends with its grading: strong recommendation, low quality of evidence, no dissent. CD is celiac disease. ACG's reason is that, in its assessment, celiac disease falls short of some of the main World Health Organization screening criteria. ACG's guideline index dates the guideline January 2023; the day is PubMed's issue date, and it was first published online September 21, 2022. A 2024 correction exists that we could not read; the quote is from the current online text.
We recommend case finding to increase detection of CD in clinical practice
Our note: An excerpt of item 7A, with the same grading: strong recommendation, low quality of evidence, no dissent. ACG uses case finding for testing groups at increased risk, such as first-degree family members, and active case finding for blood tests in patients whose symptoms or other conditions are closely tied to celiac disease, which it calls the favored strategy. It adds that case finding will miss most undiagnosed cases across the population. Not a recommendation to screen symptom-free adults in general. Dated as the row above.
Consider testing of asymptomatic relatives with a first-degree family member
Our note: Key concept 4 under ACG's question 7, an excerpt: the sentence ends by requiring that the family member's diagnosis be confirmed. ACG says key concepts are added to help implement its graded recommendations, so this carries no strength of its own and the grade is empty. The rationale in the same section is firmer, saying such patients "should be tested for CD"; we report both wordings and do not choose between them. Dated as the rows above.
Why they differ
Both bodies decline to screen the general population, and both describe the same route to a diagnosis: a tissue transglutaminase IgA blood test, then an intestinal biopsy. They differ in strength for the general population and in direction for people at risk.
- Everyone without symptoms. USPSTF (March 28, 2017) finds the evidence insufficient (I), neither for nor against. ACG (January 2023) makes a strong recommendation against mass screening. The two point the same way; ACG's is the firmer statement.
- Relatives and other higher-risk people without symptoms. USPSTF found the evidence on targeted screening inadequate as well, so its I statement covers them. ACG makes a strong recommendation for case finding, and for symptom-free first-degree relatives says to consider testing in its key concept and that they should be tested in its rationale. It defines case finding two ways in the same section: testing groups at increased risk, such as first-degree family members, and active case finding, blood testing of patients whose symptoms or other conditions are closely tied to celiac disease, which it calls the favored strategy.
- Currency. A USPSTF literature scan in May 2024 found a lack of new evidence to support an updated review, and celiac disease was not on its Recommendations in Progress list when we checked on October 9, 2026. USPSTF's summary of other bodies' positions still cites ACG's superseded 2013 guideline; the ACG rows here come from the January 2023 update. ACG published a correction to that update in 2024 that we could not read, so every ACG quote on this page is from the current online text.
What that means for you. With no symptoms and no affected relative, no body on this page recommends a test. If a parent, sibling or child has confirmed celiac disease, ACG's guideline supports asking for TTG IgA with total IgA while you are still eating gluten, and USPSTF's position does not argue against it. With symptoms, you are outside both bodies' positions on screening people without symptoms, and ACG says people with malabsorption symptoms should be tested.
3 documents set the numbers on this page. The oldest was published in 2017, the newest in 2024.
- USPSTF recommendation
- American College of Gastroenterology recommendation
- Celiac Disease: Screening, literature surveillance report (August 21, 2024) 2024
We last re-read these sources on . How we verify.
What the test involves
One blood draw, while you are eating gluten. ACG applies its testing approach at any age, as long as the person being tested is on a regular, gluten-containing diet. If you have already started a gluten-free diet, ACG says HLA testing becomes central to the approach, and that if you carry a celiac-compatible HLA type, a gluten challenge can be offered.
ACG's abstract calls antibody testing a very helpful first screen for patients suspected of celiac disease, and says intestinal biopsy is needed in most patients to confirm the diagnosis. The biopsy is taken during an upper endoscopy (EGD), and ACG specifies multiple samples from the duodenum, the first part of the small intestine: 1 or 2 from the bulb and 4 from the distal duodenum.
If the result is abnormal
A high TTG IgA. ACG sends patients with an elevated TTG IgA on to EGD with duodenal biopsy, and recommends multiple duodenal biopsies to confirm the diagnosis in children and adults (a strong recommendation on moderate-quality evidence). There is one exception, for adults with symptoms who are unwilling or unable to have an endoscopy: a high-level TTG IgA, more than 10 times the upper limit of normal, together with a positive endomysial antibody (EMA) on a second blood sample, may be taken as a diagnosis of likely celiac disease, under a conditional recommendation.
A negative result. ACG says that when the chance of celiac disease was low or moderate before the test, a negative TTG IgA in someone without IgA deficiency makes the disease unlikely. When that chance is high, it advises considering EGD with biopsy despite a negative blood test.
A confirmed diagnosis. Treatment is diet. ACG states that treatment means a strict gluten-free diet with lifelong medical follow-up, and that most patients respond very well. USPSTF: "Treatment of celiac disease is lifelong adherence to a gluten-free diet, which reverses disease manifestations in a majority of patients." For people found by screening, ACG reports that those without symptoms stay symptom-free on a gluten-free diet, that a small share report more health-related anxiety after diagnosis, and that satisfaction with the diagnosis was 93%. ACG also says newly diagnosed patients should tell their first-degree relatives about their increased risk and the recommendation for testing.
More on this screening
Frequently asked questions
My brother has celiac disease and I feel fine. Should I be tested?
ACG's guideline points toward testing, in two strengths of wording. Its key concept for first-degree relatives without symptoms says "Consider testing"; its rationale in the same section says that patients whose first-degree family member has confirmed celiac disease "should be tested for CD." Neither is a graded recommendation. USPSTF found inadequate evidence on targeted screening of people at increased risk, including those with a family history, so its I statement covers you, neither for nor against. If you and your clinician decide to test, ACG's test is TTG IgA with total IgA, taken while you are still eating gluten. Neither body says how often to retest after a negative result. If more than one relative has celiac disease, ACG says screening then reaches every other family member, second-degree relatives included.
I have no symptoms and no family history. Is a screening test worth it?
No body on this page recommends one. ACG makes a strong recommendation against mass screening, and USPSTF finds the evidence insufficient for anyone without symptoms. USPSTF's figures show the problem: at a prevalence of about 1%, a positive blood test in the general population is right only 12% to 40% of the time, so on those figures most positive results would be false (our arithmetic), and ACG sends an elevated result on to endoscopy. USPSTF also notes that some people diagnosed with celiac disease may never develop symptoms or complications.
I already stopped eating gluten. Can I still be tested?
Tell your clinician before any test. ACG's testing approach assumes you are on a regular, gluten-containing diet. For people who have already started a gluten-free diet, ACG says HLA testing becomes central, and that a gluten challenge can be offered to people who carry a celiac-compatible HLA type. If you suspect celiac disease and are still eating gluten, ACG's guideline has you tested on that diet, so do not cut gluten out first.
My TTG IgA came back high. Do I have celiac disease?
Not yet confirmed. ACG says patients with an elevated TTG IgA should proceed to an upper endoscopy (EGD) with multiple biopsies of the duodenum, and that most patients need a biopsy to confirm the diagnosis. The exception is an adult with symptoms who is unwilling or unable to have an endoscopy: a TTG IgA above 10 times the upper limit of normal plus a positive endomysial antibody on a second blood sample may be taken as a diagnosis of likely celiac disease, under a conditional recommendation. ACG's approach applies to people still eating gluten, so ask before you change your diet.
Which symptoms should make me ask for a test?
ACG says to test anyone whose symptoms, signs or lab results suggest malabsorption, such as chronic diarrhea with weight loss, fatty stools (steatorrhea), abdominal pain or bloating, and to check people with unexplained high liver enzymes. USPSTF adds the less obvious presentations: anemia, osteoporosis, chronic fatigue, peripheral neuropathy or ataxia, short stature, mouth ulcers (aphthous stomatitis), dermatitis herpetiformis, infertility and recurrent fetal loss. People with type 1 diabetes and any suggestive symptoms or signs should be tested, ACG says. With symptoms, you are outside both bodies' positions on screening people without symptoms.